
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Fi…
PVLA is up 8.12% today. Volume is 207.6K vs a 30-day average of 229.0K (0.91x).
Palvella Therapeutics, Inc. is scheduled to report earnings Tue, Nov 17, 2026. Analysts expect EPS of $-1.83. Stocks often move sharply on earnings day.

Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Fi…

Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic lymphatic malformations. The company has completed an FDA N…
William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.